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Book Review
INCENTIVES FOR GLOBAL PUBLIC HEALTH:
PATENT LAW AND ACCESS TO ESSENTIAL MEDICINES
Editors: Thomas Pogge*, Matthew Rimmer**, Kim Rubensteinm
This portrait of the global debate over patent law and access to
essential medicines focuses on public health concerns about HIV/AIDS,
malaria, tuberculosis, the SARS virus, influenza and diseases of poverty.
The essays explore the diplomatic negotiations and disputes in key
international forums, such as the World Trade Organization (WTO), the
World Health Organization (WHO) and the World Intellectual Property
Organization (WIPO).
Drawing upon international trade law, innovation policy, intellectual
property law, health law, human rights and philosophy, the authors seek to
canvass policy solutions that encourage and reward worthwhile
pharmaceutical innovation while ensuring affordable access to advanced
medicines. A number of creative policy options are critically assessed,
including the development of a Health Impact Fund, prizes for medical
innovation, the use of patent pools, Open Source drug development and
forms of 'creative capitalism'.
. Thomas Pogge is the Leitner Professor of Philosophy and International Affairs at Yale University,
Professorial Fellow at the ANU Centre for Applied Philosophy and Public Ethics, the Research Director at
the Oslo University Centre for the Study of Mind in Nature and an Adjunct Professor at the University of
Central Lancashire.
. Matthew Rimmer is a senior lecturer and Associate Director of Research at the ANU College of Law and
the Associate Director of the Australian Centre for Intellectual Property in Agriculture.
"' Kim Rubenstein is the Professor and Director of the Centre for International and Public Law at the ANU
College of Law, Australian National University.
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INCENTIVES FOR GLOBAL PUBLIC HEALTH:
PATENT LAW AND ACCESS TO ESSENTIAL MEDICINES
Reviewer: Stephanie Snyder*
I. INTRODUCTION
It is often claimed that only ten percent of global health research is
devoted to conditions that account for ninety percent of the global disease
burden.' When one notes the staggering profits made by pharmaceutical
companies in developing the drugs that pertain to that smaller percentage
of global diseases, the claim is perhaps less surprising.2 Pharmaceutical
researchers and patent advocates insist that without the financial incentive
for undertaking the development of drugs for neglected diseases, the
traditional drug process falls apart. The research and development system
cannot sustain itself on mere goodwill. Human rights activists and
healthcare supporters argue that the greed of the patent holding
pharmaceutical companies cannot be allowed to dictate the health of vast
numbers of the human population.
In May 2008, a workshop of this same title was held at the Australian
National University. Aimed at a vigorous discussion on the intersection of
international and public law with a focus on health, the workshop resulted
in the presentation of twenty papers by researchers and more than ten other
presentations. The book is a compilation of those papers outlining the
patent/access debate and proposing solutions from four areas: international
trade, innovation, intellectual property and healthcare. As discussed in
Section III below, the compiled papers present a range of proposals that
ultimately succeed only in illustrating the dire need for international
coordination and cooperation in devising a solution.
Stephanie Snyder is a third year law student at DePaul University College of Law. Stephanie is the Editor
in Chief of the DePaul Journal of Art, Technology & Intellectual Property Law and graduated from
Northwestern University in 2006.
1. Sameera Al-Tuwaijri ET AL., The 10/90 Report on Health Research, GLOBAL FORUM FOR HEALTH
RESEARCH, 2003-2004, available at www.globalforumhealth.org/Media-Publications/Publications/10-90-
Report-2003-2004.
2. See generally Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected
Diseases, DRUGS FOR NEGLECTED DISEASES WORKING GROUP, 2001, available at
www.doctorswithoutborders.org/publications/reports/2001/fatal-imbalance short.pdf.
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II. SYNOPSIS
In introducing the essays that compile this book, the editors made
note of three components that make up the overall "lack of access" issue:
(1) The medicines that could treat or cure the diseases concentrated in
the world's poor are neglected by pharmaceutical researchers precisely
because those who need them cannot afford them.' A poor consumer base
does not an enviable profit make.
(2) The medicines that are currently available for neglected diseases
are priced at a cost that no needful patient in a least developed country
(LDC) could dream of paying.'
(3) In the countries where these neglected diseases and needful
patients are located, the health infrastructure that would deliver essential
medicines is virtually nonexistent. Without clinics, hospitals, or even
doctors to administer the medication, the point of cost-related access
nearly becomes moot.'
The essays compiled by the editors address all three components as
well as the "three Ds" of the pharmaceutical process: discovery,
development, and delivery of essential medicines. The book is structured
into four viewpoints from which the issues are discussed. Analysis is
provided through the lenses of international trade, innovation, intellectual
property, and healthcare.
A. International Trade
The first four essays in the book address the access issue as viewed
through international trade and public law. The trade section begins with
an essay by Rochelle Dreyfuss' that lays out the background for
understanding the rest of the book: an explanation of the TRIPS
Agreement, the Doha Declaration, and their relationships to
pharmaceutical drug patents in particular. Dreyfuss argues that TRIPS
Council is not taking advantage of the expertise vested in the various
available international institutions such as WIPO and WHO.' Without
coordination of knowledge among these institutions, the access problem
will simply continue to grow. Building on the background set out by
3. Thomas Pogge, Matthew Rimmer, & Kim Rubenstein, Incentives for Global Public Health: Patent Law
and Access to Essential Medicines 4 (2010).
4. Id. at 5.
5. Id. at 6.
6. Rochelle C. Dreyfuss, TRIPS and essential medicines: must one size fit all? Making the TWO responsive
to the global health crisis, in Pogge, supra note 3 at 35.
7. Id. at 46-55.
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Dreyfuss, Andrew Mitchell and Tania Voon' continue by discussing the
Doha Declaration in detail and presenting an argument that provisions
similar to those therein should be formally implemented into the TRIPS
Agreement by amendment. However, the authors argue that these
provisions should only be made permanent after an evaluation by WTO
members of their efficacy in light of regional patent systems and the
"TRIPS-Plus" agreements made by many members.' Hitoshi Nasu'so
essay is a natural follow-up to Mitchell and Voon; he argues fervently
against TRIPS-Plus agreements precisely because they decrease the
efficacy of the Doha provisions with respect to essential medicine access."
The fourth essay in the trade section finally addresses the true issue of the
compilation: the battle between patent rights as protection for innovation
and the need for assurances that essential medicines can still be made
available. There, Elizabeth Siew-Kuan Ng 2 clearly lays out the debate at
hand and intimates that the compulsory licensing provisions of TRIPS and
Doha could be the appropriate answers.
B. Innovation
The second section of essays in the book addresses innovative
proposals for solutions to the tug-of-war between patent rights and access
to essential medicines. The first paper proposes Thomas Pogge'sl3 Health
Impact Fund - "an international agency that would provide a standing
option to register any new medicine for health impact rewards." 4
Heralded throughout the rest of the book as at least the most unusual
proposal, if not the most practical, Pogge describes a system that requires a
minimum of $6 billion in seed money and a means of quantifying the
"health impact" of each drug provided to LDCs by pharmaceutical
companies who elect to participate.'" The proposal begs many questions,
some of which are addressed in the next article by Kathleen Liddell.16
8. Andrew D. Mitchell and Tania Voon, The TRIPS waiver as a recognition of public health concerns in
the WTO, in Pogge, supra note 3 at 56.
9. Id. at 68-69.
10. Hitoshi Nasu, Public law challenges to the regulation of pharmaceutical patents in the US bilateral
free trade agreements, in Pogge, supra note 3 at 77.
11. Id. at 78-86.
12. Elizabeth Siew-Kuan Ng, Global health and development: patents and public interest in Pogge, supra
note 3 at 101.
13. Thomas Pogge, The Health Impact Fund: better pharmaceutical innovations at much lower prices, in
Pogge, supra note 3 at 135.
14. Pogge, supra note 3 at 25.
15. Pogge, supra note 13 at 151.
16. Kathleen Liddell, The Health Impact Fund: A critique, in Pogge, supra note 3 at 155.
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Although her essay is based on a previous version of Pogge's proposal,
many of the glaring holes still exist and warrant Liddell's discussion,
including concerns about pharmaceutical companies' possible attempts at
gaming the system. The next authors, William W. Fisher and Talha
Syed," propose another novel reorganization to the process of
pharmaceutical research and development: a prize system. They define
and illustrate the two different models of prize systems - "push" and
"pull" - and engage in a discussion of whether either system is suited to
the type of incentive that patent advocates say is required to drive research
and development of drugs for neglected diseases. To round out the
innovation section, Thomas Faunce" presents a chapter arguing for the
implementation of both safety and sanitary measures on trade in health
technologies. Faunce notes that regulations of this nature are necessary to
explicitly protect the public interest that is ostensibly at the heart of these
trade arrangements in the first place.
C. Intellectual Property
As a transition between the innovation and intellectual property
sections of the book, the essay by Dianne Nicol and Jane Nielsen" fittingly
considers a new "disease-specific" style of patent pools as an innovative
option for fueling the "discovery, development, delivery" cycle of
pharmaceutical products. Upon determining that a delivery-focused patent
pool would reap the greatest results for the participants, the authors temper
their hopes by noting that the anti-competitive effects of patents pools can
be counterproductive.20 Krishna Ravi Srinivas2 1 continues the theme of
inventive uses of relatively old tricks by discussing the possibility of an
open source drug discovery program. Noting the success of open source
software, he argues that new means of stimulating creative solutions could
be quite successful. Switching gears from hypothetical solutions to actual
case studies, Charles Lawson and Barbara Hocking's 22 article analyzes the
17. William W. Fisher & Talha Syed, A prize system as a partial solution to the health crisis in the
developing world, in Pogge, supra note 3 at 181.
18. Thomas Faunce, Innovation and insufficient evidence: the case for a WTO-WHO Agreement on Health
Technology Safety and Cost-Effectiveness Evaluation, in Pogge, supra note 3 at 209.
19. Dianne Nicol & Jane Nielsen, Opening the dam: patent pools, innovation and access to essential
medicines, in Pogge, supra note 3 at 235.
20. Id. at 254-59.
21. Krishna Ravi Srinivas, Open Source drug discovery: a revolutionary paradigm or a Utopian model?,
in Pogge, supra note 3 at 263.
22. Charles Lawson & Barbara Ann Hocking, Accessing and benefit sharing avian influenza viruses
through the World Health Organization: a CBD and TRIPS compromise thanks to Indonesia's sovereignty
claim?, in Pogge, supra note 3 at 284.
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conflict that arose between Indonesia and its obligations under the United
Nations' Convention on Biological Diversity during the H5N1 outbreaks
there. The authors use this case to illustrate the need they perceive for
flexible international intellectual property protection obligations in less-
developed countries. The final article in the intellectual property section is
the only article in the book to address a form of IP other than patents -
Matthew Rimmer" discusses the use of trademarks and celebrity
endorsements in efforts to raise money for and lend awareness to the
access issue. Drawing on themes of corporate social responsibility and
"creative capitalism," Rimmer argues that these seemingly successful
techniques can be detrimental to the causes they intend to promote,
especially when challenged on the questions of transparency,
accountability and sustainability.24
D. Healthcare
The final section of essays is focused on the issue of human rights
and the right to health. This section continues with the format of
discussions on specific cases instead of hypothetical policy proposals.
Noah Novogrodsky's25 article is unique to the volume in that it discusses
actions taken by and available to non-state actors, specifically NGOs. He
laments the current role of NGOs as advisors to international councils and
delegations and is in favor of a less passive path for the organizations.
Two examples of that less passive path are discussed by Katherine
Young.26 She compares two legal actions, one in South Africa27 and one in
Ghana,28 where non-state actors succeeded in drawing the attention of the
courts to the issue of a constitutional right to health. A third country with
a constitutional right to health - India - is discussed in Rajshree
Chandra's29 article. Chandra outlines the landmark success of generic
manufacturers over a patent owner for the leukemia drug Glivec.30 The
23. Matthew Rimmer, The Lazarus Effect: the (RED) Campaign and creative capitalism, in Pogge, supra
note 3 at 313.
24. Id. at 336.
25. Noah Benjamin Novogrodsky, Beyond TRIPS: the role of non-state actors and access to essential
medicines, in Pogge, supra note 3 at 343.
26. Katharine G. Young, Securing health through rights, in Pogge, supra note 3, at 357.
27. Pharmaceutical Manufacturers' Association of South Africa v. President of the Republic of South
Africa, Case No. 4183/98 (High Court of South Africa).
28. Jeremy Perelman and Lucie White, Stones of Hope: How African Activists Reclaim Human Rights to
Challenge Global Poverty (2010, forthcoming).
29. Rajshree Chandra, The role of national laws in reconciling constitutional right to health with TRIPS
obligations: an examination of the Glivec patent case in India, in Pogge, supra note 3 at 38 1.
30. Novartis AG et. al v. Union of India et. al (6 August 2007, High Court of Judicature at Madras for W.P.
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unusual circumstances of that case lead to the drug being available in
India, then removed from treatment plans of patients who couldn't afford
it once Novartis was granted exclusive marketing rights." Subsequently,
generic manufactures succeeded in having Novartis' patent application
rejected, opening the door for cost-effective generic versions of the drug to
come back into the worldwide market.3 2 Illustrating another avenue for the
provision of inexpensive drugs in an LDC, Jonathon Burton-MacLeod"
discusses the problems Thailand has had implementing the sections of
TRIPS that allow for compulsory licensing of patented drugs. In its
attempt to bring AIDS and heart disease drugs to its citizens, Burton-
MacLeod argues that Thailand has exposed the grave inadequacies that
still remain in the supposed flexibilities of TRIPS.
III. EVALUATION
The editors of this text have made noble overtures toward addressing
the problem of essential medicine access. The diversity of the essays in
the volume and the credentials of their respective authors both make clear
the efforts being made towards finding a solution. Perhaps the best aspect
of the book as a whole is the feeling that one has when coming away from
it: a feeling that such an immense problem is, in fact, being addressed with
seriousness and vigor. Similarly encouraging are the innovative proposed
uses for existing aspects of the patent regime, such as patent pools. It is
frequently suggested that the U.S. patent system may need to be almost
completely dismantled to accommodate global health issues; the proposals
in this book indicate that we should not be so rash. Unfortunately, a
further look at the book reveals that the bold plans of the authors inside are
not without flaws.
The primary defect in the volume is that many of the articles contain
oversimplified assumptions of fact that are too glaring to ignore. For
example, Pogge, in explaining his Health Impact Fund (HIF), notes that
the six billion dollars in initial funding could be collected by taxing every
citizen of the world 0.01 percent of his or her gross income and pooling
that collection into the HIF. Although this is probably intended as a
demonstration of the "drop in the bucket" of the world's wealth that could
kick off the HIF, this example is not followed up by any kind of discussion
Nos. 24759 and 24760 of 2006).
3 1. Id.
32. Id.
33. Pogge, supra note 3 at 406.
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of where this funding could come from in reality. There is no
acknowledgement of the extreme difficulty the U.S. government in
particular has in enacting even tiny tax hikes. When one realizes that there
is not even a superficial evaluation of possible funding sources, the
hopeful proposal for HIF deflates almost instantaneously. Secondly, not
all of the articles seem to truly belong in the volume. For example,
Rimmer's article on trademarks and celebrity endorsements for
foundations and fundraising makes only tenuous links between the main
topic and the problem of access to medicine. In reading the book straight
through, the Rimmer article jumps out as almost a commercial break -
something to attract your attention away from the dark issues being
discussed by waving names-like Bill Gates and Bono - in front of your
eyes.
Many of these flaws, though, are somewhat inevitable when one
considers the seriousness and complexity of the problem at hand. To
suggest that workable solutions could be outlined in papers under thirty
pages is certainly naYve. The so-called "blind spots" in many of the
articles are understandable: the authors in each section are experts in their
fields but cannot be expected to have mastered the intricacies of each of
the other areas of law and policy this book attempts to cover. Because
each of the four sections hosts its own experts, many of the holes in logic
are filled by reference to other articles in other sections. However, this is
not readily apparent as it can be cumbersome to read an entire compilation
of essays straight through. If one is to read and digest each of the essays
separately, this problem persists.
I would recommend this book, albeit with reservations, to anyone
with an interest in solving the access to medicines issue. One must have a
clear idea of what the book sets out to be, and perhaps more importantly, a
clear idea of what the book is not. It is not a primer; coming in with little
to no background knowledge of US and international patent regimes and
global health issues is not advisable. Such an approach could easily leave
a reader frustrated and disinterested. What the book does well is present
preliminary proposals for alleviating this worldwide problem. With the
right set of preexisting knowledge and goals, the framework in these
essays is the perfect foundation upon which to build the eventual solution
to this problem.
IV. CONCLUSION
This book is a useful resource as a compilation of discussions on the
causes of the access to medicine issue, as well as proposals for and
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critiques on potential solutions. In the end, most of the proposals
presented are more precisely categorized as "pre-proposals." For a
policymaker who endeavors to finally resolve the access issue, this book
holds the germinations of several potentially viable solutions. It is most
useful, then, as a jumping-off point for further research and policy
development instead of as an anthology on existing policy and law on the
issue.

